Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options.

The Korean Journal of Internal Medicine
Inkeun Park, Jae Lyun Lee

Abstract

After cisplatin-based chemotherapy became the standard treatment for metastatic urothelial cancer (mUC), very little progress has been made in the treatment landscape of this condition until recently. With increased knowledge about the molecular biology of mUC and advances in the field of cancer immunobiology, there has been an explosion in the number of clinical trials for mUC, and systemic treatment of mUC is rapidly changing. Despite the availability of several novel therapeutic agents, cisplatin-based cytotoxic chemotherapy remains the standard, first-line treatment option. Immune checkpoint inhibitors (ICIs), including programmed death-1 and programmed death ligand-1 inhibitors, are preferred second-line treatment options that are also used in first-line cisplatin-ineligible settings. For patients with actionable fibroblast growth factor receptor 2 (FGFR2) or FGFR3 genomic alterations, erdafitinib can be considered after platinum-based treatment. Enfortumab vedotin, a monoclonal antibody targeting nectin-4 conjugated to monomethyl auristatin E, has been approved for patients who do not respond to both cytotoxic chemotherapy and ICIs. In this review, we address the clinical trial data that have established the current stand...Continue Reading

References

Jul 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerB A Lowe
Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J LogothetisR G Kilbourn
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B J RothP J Loehrer
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R S WitteP J Loehrer
Nov 18, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M StadlerF A Dorr
Dec 16, 1998·Investigational New Drugs·R S WitteP J Loehrer
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F BajorinM G Boyle
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J MooreL Seymour
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C N SternbergUNKNOWN European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
Feb 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J VaughnAvi B Markowitz
Aug 15, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H Soto ParraA Santoro
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BamiasUNKNOWN Hellenic Cooperative Oncology Group
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Sep 1, 2005·Nature Clinical Practice. Oncology·Supriya G Mohile, Walter M Stadler
Dec 7, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C N SternbergUNKNOWN EORTC Genito-Urinary Cancer Group
Jul 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher J SweeneyDonald S Kaufman
Dec 6, 2006·Investigational New Drugs·Matthew D GalskyDean F Bajorin
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maha H A HussainUNKNOWN National Cancer Institute
Sep 14, 2007·Acta Oncologica·Anne Birgitte AlsHans Von Der Maase
Jan 27, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G K PhilipsUNKNOWN Cancer and Leukemia Group B
Aug 19, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntHans von der Maase
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntJonathan E Rosenberg
Nov 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Linda LeeMonika K Krzyzanowska
Feb 18, 2011·Assay and Drug Development Technologies·Ellen E CoddChristopher M Flores
May 6, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D GalskyG Sonpavde
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew D GalskyJoaquim Bellmunt
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arti HurriaWilliam P Tew
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriPhilip W Kantoff
Aug 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yu-Ning WongGary Hudes

❮ Previous
Next ❯

Citations

Sep 17, 2020·Expert Review of Clinical Pharmacology·Alberto D'AngeloGiandomenico Roviello
Jun 8, 2021·Frontiers in Oncology·Yi LiChong Li

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02603432
NCT02807636
NCT02853305
NCT03898180
NCT03390504
NCT02780687
NCT03474107
NCT03288545
NCT04223856
NCT03547973

Software Mentioned

MyPathway
IMvigor

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Review of Anticancer Therapy
Kamaneh Montazeri, Guru P Sonpavde
Investigative and Clinical Urology
Whi An Kwon, Ho Kyung Seo
© 2021 Meta ULC. All rights reserved